New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
08:06 EDTEXASExact Sciences announces DeeP-C study results published
Exact Sciences announced that results from its DeeP-C clinical study have been published online in the New England Journal of Medicine. The peer-reviewed study, “Multi-target Stool DNA Testing for Colorectal-Cancer Screening” will also appear in the journal’s April 3 print issue. The company said, "In our clinical study, the data show that Cologuard, the multi-target stool-based DNA test, is highly sensitive in detecting colorectal cancer and higher risk pre-cancerous polyps in a large, diverse average-risk patient population and has the potential to be an important screening tool.” The Exact Sciences Cologuard screening test is an investigational device currently under review by the U.S. Food and Drug Administration and is not available for sale in the U.S. The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to review Exact Science’s PMA application for Cologuard on March 27.
News For EXAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
09:54 EDTEXASAetna not reimbursing Exact Sciences for more than what law requires, says Maxim
Maxim said it views Exact Sciences' (EXAS) pact with Aetna (AET) for coverage for the Cologuard test for Medicare Advantage members as an incremental positive and the firm expects other insurers to follow Aetna's lead. However, the firm thinks the announcement indicates Exact Sciences has had talks with Aetna about reimbursement, but the insurer still isn't reimbursing for anything more than what the law requires of them. Maxim recommends shares be sold on the strength and reiterates its Sell rating on Exact Sciences.
07:57 EDTEXASExact Sciences says Aetna Medicare Advantage to cover Cologuard
Exact Sciences (EXAS) announced that Aetna (AET) will cover Cologuard under its Medicare Advantage plan, reaching 967,000 members across the country. The three year agreement will go into effect on April 1. Cologuard is the first and only FDA approved noninvasive stool-based DNA screening test for colon cancer. The test will be available to Aetna’s Medicare Advantage members through their physician without a co-payment or co-insurance.
February 25, 2015
08:47 EDTEXASExact Sciences weakness creates buying opportunity, says JMP Securities
Subscribe for More Information
February 24, 2015
11:50 EDTEXASExact Sciences Q1 test guidance conservative, says Mizuho
Subscribe for More Information
08:50 EDTEXASExact Sciences management to meet with William Blair
Subscribe for More Information
07:32 EDTEXASExact Sciences reports Q4 EPS (38c), consensus (39c)
Subscribe for More Information
February 23, 2015
18:02 EDTEXASOn The Fly: After Hours Movers
Subscribe for More Information
17:14 EDTEXASWEDC to provide up to $9M in tax credits to Exact Sciences
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use